A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis

Trial Profile

A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Lomibuvir (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 08 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Additional locations added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top